prof. Ingeborg Goethals (MD, PhD)

CRIG group leader
Ingeborg Goethals

Head of Clinic - Department of Nuclear Medicine (Ghent University Hospital)
Full professor - Faculty of Medicine and Health Sciences (University Ghent)
Principal Investigator Nuclear Medicine - Neuro-Oncology Research Group Ghent University Hospital / University Ghent
Member of the Board of Governors- Belgian Association Neuro-Oncology (BANO)


Research focus

As a senior nuclear medicine physician, Ingeborg Goethals, participates in the multidisciplinary neuro-oncology and head and neck cancer research groups of the Ghent University Hospital/Ghent University. These research groups have a unique expertise in clinical and preclinical multimodality imaging of (high-grade) brain and head and neck tumours for (differential) diagnosis, biopsy guidance, radiation treatment planning and therapy response assessment. The preclinical work in brain and head and neck tumours is performed in collaboration with the INovative Flemish IN vivo Imaging TechnologY (INFINITY) lab, the preclinical core imaging facility of the Ghent University.


Ingeborg Goethals is trained at the Ghent University both as a neurologist and a nuclear medicine physician. In 2004, she successfully defended her Ph. D. thesis entitled: 'Exploration of the Prefrontal Cortex by means of Neuroactivation and Receptor Imaging Studies with Single Photon Emission Tomography'. She is a senior nuclear medicine physician at the department of nuclear medicine of the Ghent University Hospital. As a senior staff member, she is dedicated to conventional nuclear medicine, PET-CT imaging in oncology and inflammatory and infectious diseases, as well as PET and SPECT imaging of the brain with an emphasis on refractory epilepsy, cognitive impairment and dementia, brain and head and neck tumours. She is also the trainer of the residents-in-training for nuclear medicine at the Ghent University Hospital. She is also the principal investigator of research multimodality imaging of brain and head and neck tumours. She already published many original papers both in national and international journals (see PubMed for complete list of publications). She is also the promotor and supervisor of PhD students: working in the field of imaging of (neuro)oncology.

Research team

  • prof. Ingeborg Goethals - principal investigator, full professor
  • dr. Jeroen Verhoeven (PhD) - postdoctoral fellow
  • Marjan Acou - doctoral fellow
  • Jannes Gavel - medical student
  • Vincent Matthijs - medical student

Key publications

  • ‘Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma’. Front. Oncol. 2019. (accepted for publication)
  • ‘Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model’. Radiat Oncol., 2019. (PMID: 31146757)
  • ‘New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastoma’. Sci. Rep., 2019 (PMID: 30814660)
  • ‘The path toward PET-guided radiation therapy for glioblastoma in laboratory animals: a mini review’. Front. Med., 2019. (PMID: 30761302)
  • ‘Magnetic resonance imaging-guided radiation therapy using animal models of glioblastoma’. Br. J. Radiol., 2019 (PMID: 30563357)
  • ‘Machine learning based brain tumour segmentation on limited data using local texture and abnormality’. Comput. Biol. Med., 2018 (PMID: 29763764)
  • ‘A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory’. Strahlenther. Onkol., 2018 (PMID: 29556677)
  • ‘PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator’. J. Vis. Exp., 2017 (PMID: 29364211)
  • 'In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats'. Mol Imaging Biol., 2017. (PMID: 28303489)
  • '18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria'. Nucl. Med. Commun., 2017. (PMID: 27984537)
  • 'Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer'. Acta. Oncol., 2017. (PMID: 28885076)
  • 'Long-term outcome of 18 F-fluorodeoxyglucose-positron emission tomography-guided dose painting for head and neck cancer: Matched case-control study'. Head Neck, 2017. (PMID: 28833829)
  • 'Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats'. PLoS One, 2016. (PMID: 27559736)
  • '(18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study'. Nucl Med Biol, 2015. (PMID: 25218024)
  • 'MRI-guided 3D conformal arc micro-irradiation of a F98 glioblastoma rat model using the Small Animal Radiation Research Platform (SARRP)'. J Neurooncol, 2014. (PMID: 25069566)
  • 'Validation of 18F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas: a stereotactic PET and MRI study'. Clin. Nucl. Med., 2013. (PMID: 23640217)
  • 'The optimal timing for imaging brain tumours and other brain lesions with 18F-labelled fluoromethylcholine: a dynamic positron emission tomography study'. Nucl Med Commun, 2012. (PMID: 22842224)

Contact & links